SI4010082T1 - Multispecifična protitelesa anti-TCR delta variable 1 - Google Patents

Multispecifična protitelesa anti-TCR delta variable 1

Info

Publication number
SI4010082T1
SI4010082T1 SI202130032T SI202130032T SI4010082T1 SI 4010082 T1 SI4010082 T1 SI 4010082T1 SI 202130032 T SI202130032 T SI 202130032T SI 202130032 T SI202130032 T SI 202130032T SI 4010082 T1 SI4010082 T1 SI 4010082T1
Authority
SI
Slovenia
Prior art keywords
antibodies
tcr delta
multispecific anti
delta variable
variable
Prior art date
Application number
SI202130032T
Other languages
English (en)
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Original Assignee
GammaDelta Therapeutics Limited,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI4010082(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Application filed by GammaDelta Therapeutics Limited, filed Critical GammaDelta Therapeutics Limited,
Publication of SI4010082T1 publication Critical patent/SI4010082T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
SI202130032T 2020-08-14 2021-08-14 Multispecifična protitelesa anti-TCR delta variable 1 SI4010082T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies
EP21756070.5A EP4010082B1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (1)

Publication Number Publication Date
SI4010082T1 true SI4010082T1 (sl) 2023-04-28

Family

ID=80247426

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202130032T SI4010082T1 (sl) 2020-08-14 2021-08-14 Multispecifična protitelesa anti-TCR delta variable 1

Country Status (18)

Country Link
EP (7) EP4269445B1 (sl)
JP (1) JP2023537534A (sl)
KR (1) KR20230083267A (sl)
CN (1) CN116209456A (sl)
AU (1) AU2021323512A1 (sl)
BR (1) BR112023002741A2 (sl)
CA (1) CA3188682A1 (sl)
CO (1) CO2023003009A2 (sl)
DK (2) DK4010082T5 (sl)
ES (1) ES2943063T3 (sl)
FI (2) FI4269444T3 (sl)
IL (1) IL300517A (sl)
LT (2) LT4269444T (sl)
MX (1) MX2023001728A (sl)
PL (1) PL4010082T3 (sl)
PT (2) PT4010082T (sl)
SI (1) SI4010082T1 (sl)
WO (1) WO2022034562A1 (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010082T (pt) 2020-08-14 2023-04-26 Gammadelta Therapeutics Ltd Anticorpos multiespecíficos anti-tcr variável delta 1
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
WO2024193459A1 (en) * 2023-03-17 2024-09-26 Nanjing Legend Biotech Co., Ltd. METHODS OF CULTURING Vδ1 T CELLS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
EA201890013A1 (ru) 2015-06-09 2018-07-31 Лимфакт - Лимфоцит Активэйшн Текнолоджис, С.А. Способы получения tcr гамма дельтат-клеток
IL315329A (en) 2015-10-30 2024-10-01 Cancer Research Tech Limited Expansion of non-blood cell-resident gamma delta T cells and uses of these cells
WO2017197347A1 (en) 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3490675A4 (en) 2016-07-29 2020-07-29 New York University T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
WO2019005637A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
EA202190773A1 (ru) * 2018-09-19 2021-06-21 Лава Терапьютикс Б.В. CD1d ИММУНОГЛОБУЛИН ДВОЙНОГО ДЕЙСТВИЯ
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
JP2022525435A (ja) 2019-04-08 2022-05-13 メモリアル スローン ケタリング キャンサー センター Ｃｄ１９抗体およびこれを使用する方法
BR112022001416A2 (pt) 2019-08-16 2022-06-21 Gammadelta Therapeutics Ltd Populações de células t gama delta ex vivo
JP2022544683A (ja) 2019-08-16 2022-10-20 ガンマデルタ セラピューティクス リミテッド 新規な抗ｔｃｒデルタ可変１抗体
PT4010082T (pt) 2020-08-14 2023-04-26 Gammadelta Therapeutics Ltd Anticorpos multiespecíficos anti-tcr variável delta 1
WO2022175414A1 (en) 2021-02-17 2022-08-25 Adaptate Biotherapeutics Ltd. Multispecific anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
EP4218932A2 (en) 2023-08-02
MX2023001728A (es) 2023-04-20
EP4269444B1 (en) 2024-06-26
JP2023537534A (ja) 2023-09-01
PT4010082T (pt) 2023-04-26
ES2943063T3 (es) 2023-06-08
FI4269444T3 (fi) 2024-09-20
EP4265643B1 (en) 2024-06-26
EP4010082A1 (en) 2022-06-15
EP4010082B1 (en) 2023-01-25
PL4010082T3 (pl) 2023-05-29
EP4269444A2 (en) 2023-11-01
IL300517A (en) 2023-04-01
BR112023002741A2 (pt) 2023-10-10
KR20230083267A (ko) 2023-06-09
EP4269446B1 (en) 2024-06-26
EP4269445B1 (en) 2024-06-26
DK4010082T5 (da) 2024-08-05
CO2023003009A2 (es) 2023-03-17
CN116209456A (zh) 2023-06-02
EP4218932A3 (en) 2023-09-27
AU2021323512A1 (en) 2023-04-13
EP4269445A2 (en) 2023-11-01
EP4269446A3 (en) 2024-02-14
EP4269445A3 (en) 2024-02-14
PT4269444T (pt) 2024-09-05
FI4010082T3 (fi) 2023-04-04
EP4269446A2 (en) 2023-11-01
EP4265642A2 (en) 2023-10-25
LT4269444T (lt) 2024-09-25
DK4269444T3 (en) 2024-08-19
EP4265643A3 (en) 2024-02-14
EP4265642B1 (en) 2024-06-26
EP4269444A3 (en) 2024-02-14
DK4269444T5 (da) 2024-08-26
CA3188682A1 (en) 2022-02-17
EP4265643A2 (en) 2023-10-25
DK4010082T3 (da) 2023-04-03
EP4265642A3 (en) 2024-02-14
LT4010082T (lt) 2023-03-10
WO2022034562A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
DK4269444T3 (en) Multispecific anti-tcr delta variable 1 antibodies
LT3872091T (lt) Antikūnai prieš sars-cov-2
IL290537A (en) Therapeutic uses of anti-tcr variable delta 1 antibodies
IL308741A (en) Anti-SIRP-alpha antibodies
EP4243871A4 (en) MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
GB202010652D0 (en) Anti-tau antibodies
GB202102222D0 (en) Multispecific anti-TCR delta variable 1 antibodies
IL311043A (en) Anti-IL---11RA antibodies
GB202203226D0 (en) Trays
IL307332A (en) New multispecific antibodies
GB202111685D0 (en) Anti-tcr delta variable 1 antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
GB202105110D0 (en) Anti-CD73 antibodies
GB202014851D0 (en) SARS-COV-2 antibodies
GB202102224D0 (en) Anti-TRC delta variable 1 antibodies
GB201901045D0 (en) Variable wheelbase combine
IL310245A (en) Anti-HLA-G antibodies
GB202208773D0 (en) Anti-SARS2-S antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies
GB202112297D0 (en) Antibodies
IL299767A (en) Antibodies against Alpha-4-Beta-7